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Treatment 
• Several different treatment options • Severe Cases of COVID-19: 
once the virus has been contracted • Respiratory failure/ARDS 
• Antivirals • Supplemental Oxygen: 
• Remdesivir • Ventilator Support 
• Oseltamivir • Noninvasive Oxygen 
• Umifenovir Strategy (NIOS) 
• Steroids • i.e. CPAP/BIPAP and 
• Plasma Therapy Heated High Flow. 
• Supplemental Oxygen support • Continuous Renal Replacement 
Therapy 
• (Nikose et al., 2020) • Prone Position technique 
(Binda et al., 2021) 
(Allorhythmia for 
Prone Position 
Therapy, Binda et 
al., 2021) 
(Prone Position, 
Binda et al., 2021)
Prone Position Therapy 
• Intubated patients require six total 
• 
• (Binda et. al., 2021) 
What Topic? 
SARS-CoV-2 (COVID-19) 
• A Virus that primarily affects the 
respiratory tract (Yuki et al., 2020) 
Why SARS-CoV-2? 
• Over 18 million people have been 
infected by the virus in the span of 
a year. Labeling this virus a global 
pandemic (Nikose et al., 2020). 
• Symptoms for COVID-19 range 
from mild to severe with end organ 
failure (Yuki et al., 2020). 
• 34,067,912 confirmed cases and 
608,884 deaths in the United States 
alone (John Hopkins University of 
Medicine, 2021) 
(COVID-19 confirmed deaths, Our World 
In Data, 2021) 
Signs & Symptoms 
• Symptoms range from no 
symptoms to severe adult 
respiratory distress syndrome 
(ARDS) 






• (Binda et al., 2021) 
Underlying 
Pathophysiology 
• COVID-19 enters the body via close 
contact or an individual coughing 
the viral particles into the air. 
• The virus binds to the host cells 
and enters the cell by endocytosis 
and replicates it RNA, which makes 
viral proteins. 
• COVID-19 virus has a spike that 
comprises of two functional 
subunits: 
• S1: responsible for 
binding to the cell. 
• S2: causes fusion 
between viral 
proteins and cellular 
membrane 
• In the lungs angiotensin enzyme is 
a functional receptor site for 
COVID-19. The lungs are the 
primary organ affected by the 
virus. 
• (Yuki et. al., 2021) 
Significance Of 
Pathology 
• The pathology of this virus impacts 
the lungs, by attaching to one of the 
major enzymes ACE2 (Yuki et. al., 
2021). 
• Knowing this provides 
understanding to the disease 
process and the symptoms 
associated with the virus. 
• Dyspnea 
• Fever (host response 
to infection) 
• Low partial pressure 
of oxygen (PaO2) 
• This pathology guides are clinical 
decisions and treatment plans: 
• Ventilator support or 
CPAP/BIPAP/HHF 
• Plasma Therapy 
• Antiviral treatment 




• COVID-19 can be transmitted from 
human to human, when a healthy 
individual comes in contact with an 
infected person. 
• Can spread from asymptomatic or 
symptomatic individuals. 
• Transmission and spread is seen 
initially from family members and then 
healthcare workers who come in 
contact with infected persons. 
• Spreading of the virus can be external 
(family members/community) or in 
the body leading to end organ failure 
via the bloodstream or lymphatic 
system. 
• Preventing the spread of the virus 
requires frequent hand washing or 
utilization of 70% (V/V) alcohol based 
hand sanitizer. 
• (Nikose et. al., 2020) 
Transmission of COVID-19 into 
Lung and kidney tissue,
(Pesaresi et al., 2020) 
• Can be used with non-ventilated or 
ventilated patients. 
• Promotes better oxygen exchange 
• Pulmonary Recruitment 
• Increases Lung Volume 
• Reduces Atelectatic 
Regions 
• Preparations Prior to proning: 
• Secure endotracheal 
Tube (if applicable). 
• Lubricate eyes 
• Applying Hydrocolloid 
dressings to protect skin 
• (Binda et. al., 2021) 
healthcare works to perform safely: 
• 4 Nurses 
• 1 Respiratory Therapist 
• 1 provider that can 
reintubate if necessary 
Continuous monitoring while prone: 
• SpO2 
• Arterial Line 
• End-Tidal Carbon 
Dioxide 
• (Minimal Requirement) 
Vaccinations Complications of 
COVID-19 • Three vaccinations have come on the 
market to decrease spread and 
mortality rates, if COVID-19 is • COVID-19 can have a number of 
acquired. complications. 
• Pfizer, Moderna, and Johnson & • Respiratory failure/ARDS requiring 
Johnson have been approved by FDA ventilatory support (Jackson & 
(emergency). Wands, 2021) 
• Both Pfizer and Moderna utilize new • End organ failure: 
techniques, such as nucleic acid (DNA • Kidneys 
& RNA) • Heart 
• Brain 
• (Nikose et al., 2020) 
• Additional services maybe needed 
to treat and manage organ failure: 
References • CRRT 






• (Yuki et. al., 2021) 
Conclusion 
• COVID-19 is a virus that has Vaccines approved by FDA, (Center 
impacted millions around the for Disease Control and Prevention 
world causing a global pandemic. [CDC], 2021) 
• The virus primarily impacts the 
lungs, but can have a multiorgan 
impact with patients (Pesaresi et. Nursing Care al., 2020). 
• Care for COVID-19 patients: • Several treatment options are 
available to support mild or severe 
• Supportive care and managing cases of COVID-19: 
symptoms: • Vaccines 
• Fever (Tylenol, ice • Antivirals 
packs, etc.) • Ventilatory support 
• Dyspnea (Oxygen) • Prone Therapy 
• Cough • NSAIDS 
• Muscle Aches • (Nikose et. al., 2020) 
(Motrin) 
• Phycological Support from being • Three vaccines have been approved 
isolated from family and support by the FDA (emergently) to slow 
system. the spread of COVID-19 and 
• Virtual Calls decrease mortality rates of those 
• Phone accessibility that contract the virus (Nikose et. 
al., 2020). 
• Constant monitoring of symptoms 
progression (mild to severe). • COVID-19 can have many 
complications and requires 
• (Centers for Disease Control and supportive care and phycological 
Prevention [CDC], 2021) support for patients hospitalized. 
(Centers for Disease Control and 
Prevention [CDC], 2021) 
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